Related Experiment Video
Updated: Mar 1, 2026

Th17 Inflammation Model of Oropharyngeal Candidiasis in Immunodeficient Mice
Published on: February 18, 2015
Divergence in the approach to tumor necrosis factor α-inhibitor recipients with coccidioidomycosis
Ashley L Garrett1, Stephen S Cha2, Elizabeth Wack3
1Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA.
Background:
Tumor necrosis factor α-inhibitors (TNFIs) have been associated with increased risk of certain fungal infections, including coccidioidomycosis. The optimal treatment approach to coccidioidomycosis in TNFI recipients is unknown.
Methods:
We constructed an anonymous, voluntary survey for practicing pulmonary and infectious disease physicians in the state of Arizona regarding approach to TNFI patients with coccidioidomycosis.
Results:
There is no current consensus on managing these patients.
Conclusions:
Further research is necessary to determine the optimal approach to TNFI recipients with coccidioidomycosis.
More Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Hypersensitivity Reactions: Cytolytic Reactions
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Endocarditis III: Medical Management

